PhilArchive
open access
Grouping approaches to PFAS and industry funding: a case study on the findings of a recent panel of experts
Per- and polyfluoroalkyl substances (PFAS) are a large class of chemicals, whose carbon-fluorine bonds allow a wide range of industrial applications but also make them highly persistent. Since there is evidence about only a few of them and their properties may vary, one of the pressing issues regarding PFAS is how to group them for different purposes. In this paper, I aim to show how a recent panel of experts about grouping PFAS was co-opted in a way that favor the fluorine industry. The panel consisted of eleven experts, including authors renowned for views in conflict with fluorine industry regulatory approaches, answering questions through an online application. Its main results along with the experts’ answers were published in 2022 in the journal Regulatory Toxicology and Pharmacology. Through a detailed analysis of all the material published and in dialogue with the literature about industry-funded research, I will present how choices in the design of the panel (e.g., which kind of consensus the exercise could capture, the ways questions were framed or even changed), in textual analysis (e.g., criteria for assembling opinions) and in the communication of the findings (e.g., what gets included or excluded) were made in an industry friendly way affecting two specific grouping approaches. I conclude with some lessons about this kind of influence of industry funding.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Better Fighting Through Chemistry? The Role of FDA Regulation in Crafting the Warrior of the Future#485763
- The Capacity Cost of Informational Screening#1144044
- UC Comments on FDA's Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products; Draft Guidance for Industry; Availability (Docket No. FDA-2021-D-1214, December 9, 2021)#629324
- Biological and Chemical Transformation of Per- and Polyfluoroalkyl Substances for Contaminated Groundwater Site Management and Remediation#1106882
- Exploring Regulatory Flexibility to Create Novel Incentives to Optimize Drug Discovery#87697
Record · ID 78678
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive